Heart transplantation and anti-HLA antibodY: myocardial dysfunction and prognosis - HeartLAy study.


Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
10 2023
Historique:
received: 29 04 2023
accepted: 08 06 2023
medline: 13 10 2023
pubmed: 7 7 2023
entrez: 7 7 2023
Statut: ppublish

Résumé

The presence of anti-human leucocyte antigen (HLA) antibodies has been implicated in a higher incidence of complications as well as mortality rate in heart transplantation. The aim of the study was to identify through non-invasive parameters early signs of myocardial dysfunction in the presence of anti-HLA antibodies but without evidence of antibody-mediated rejection (AMR) and its possible prognostic impact. A total of 113 heart-transplanted patients without acute cellular rejection (ACR) and AMR or cardiac allograft vasculopathy (CAV) were prospectively enrolled and divided into two groups ['HLA+' (50 patients) and 'HLA-' (63 patients)], based on the presence of anti-HLA antibodies. Each patient was followed for 2 years after the enrolment, recording episodes of AMR, ACR, CAV, and mortality. Clinical characteristics were similar between the two groups. Among laboratory data, N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin values were significantly higher in the presence of anti-HLA antibodies (P < 0.001 and P = 0.003, respectively). The echocardiographic parameters that showed a statistically significant difference between the two groups were deceleration time of E wave (DecT E, P < 0.001), left ventricular global longitudinal strain (P < 0.001), tricuspid annular plane systolic excursion (P = 0.011), tricuspid S' wave (P = 0.002), and free wall right ventricular longitudinal strain (fwRVLS, P = 0.027), whereas left atrial strain did not differ significantly (P = 0.408). Univariate analysis showed that anti-HLA antibodies were associated with the development of CAV at both 1 and 2 year follow-up [odds ratio (OR) 11.90, 95% confidence interval (CI) 1.43-90.79, P = 0.022 and OR 3.37, 95% CI 1.78-9.67, P = 0.024, respectively]. Bivariate analysis demonstrated that both fwRVLS and DecT E were predictors of CAV development independently from HLA status. The presence of circulating anti-HLA antibodies is correlated with a mild cardiac dysfunction, even in the absence of AMR, and CAV development. Interestingly, reduced values of DecT E and fwRVLS were predictors of future development of CAV, independently from anti-HLA antibody.

Identifiants

pubmed: 37415291
doi: 10.1002/ehf2.14442
pmc: PMC10567642
doi:

Substances chimiques

Antibodies 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2853-2864

Informations de copyright

© 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

Am J Transplant. 2011 Feb;11(2):312-9
pubmed: 21219570
Eur Heart J Cardiovasc Imaging. 2015 Sep;16(9):919-48
pubmed: 26139361
J Am Soc Echocardiogr. 2018 Mar;31(3):349-360
pubmed: 29275986
JACC Cardiovasc Imaging. 2010 Oct;3(10):989-1000
pubmed: 20947044
J Heart Lung Transplant. 2017 May;36(5):567-576
pubmed: 28089194
J Transplant. 2013;2013:519680
pubmed: 23984043
ESC Heart Fail. 2023 Oct;10(5):2853-2864
pubmed: 37415291
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
J Am Coll Cardiol. 2007 Sep 11;50(11):1064-9
pubmed: 17825716
JACC Cardiovasc Imaging. 2018 Oct;11(10):1514-1530
pubmed: 30286911
J Heart Lung Transplant. 2010 Jul;29(7):717-27
pubmed: 20620917
J Am Soc Echocardiogr. 2015 Oct;28(10):1149-56
pubmed: 26165446
J Heart Lung Transplant. 2013 Dec;32(12):1147-62
pubmed: 24263017
Heart Fail Rev. 2021 Mar;26(2):319-336
pubmed: 32889634
J Heart Lung Transplant. 2016 Feb;35(2):179-85
pubmed: 26520246
J Heart Lung Transplant. 2018 May;37(5):537-547
pubmed: 29452978
Circulation. 2015 May 5;131(18):1608-39
pubmed: 25838326
Curr Opin Organ Transplant. 2019 Jun;24(3):245-251
pubmed: 31090631
J Heart Lung Transplant. 2017 May;36(5):540-545
pubmed: 27916323
Cardiovasc Ultrasound. 2009 Feb 08;7:6
pubmed: 19200402
Int J Cardiovasc Imaging. 2021 May;37(5):1621-1628
pubmed: 33442856
Echocardiography. 2020 Apr;37(4):561-569
pubmed: 32200582
J Heart Lung Transplant. 1995 Sep-Oct;14(5):856-64
pubmed: 8800720
Transpl Int. 2016 Jan;29(1):63-72
pubmed: 26340387
Transplant Proc. 2002 Sep;34(6):2174-7
pubmed: 12270355
J Am Soc Echocardiogr. 2020 Sep;33(9):1132-1140.e2
pubmed: 32653298
Exp Clin Transplant. 2008 Sep;6(3):229-35
pubmed: 18954302
Cardiovasc Ultrasound. 2021 Jan 9;19(1):6
pubmed: 33422079
Trends Mol Med. 2015 May;21(5):319-29
pubmed: 25801125
J Heart Lung Transplant. 2006 Feb;25(2):153-9
pubmed: 16446213
Clin Transplant. 1996 Dec;10(6 Pt 2):639-45
pubmed: 8996758

Auteurs

Carlotta Sciaccaluga (C)

Division of Cardiology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.

Benedetta Maria Natali (BM)

Division of Cardiology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.

Francesca Maria Righini (FM)

Division of Cardiology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.

Carlotta Sorini Dini (C)

Division of Cardiology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.

Federico Landra (F)

Division of Cardiology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.

Giulia Elena Mandoli (GE)

Division of Cardiology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.

Nicolò Sisti (N)

Division of Cardiology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.

Daniele Menci (D)

Division of Cardiology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.

Antonio D'Errico (A)

Department of Internal Medicine, University of Siena, Siena, Italy.

Flavio D'Ascenzi (F)

Division of Cardiology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.

Marta Focardi (M)

Division of Cardiology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.

Sonia Bernazzali (S)

Department of Cardiac Surgery, University of Siena, Siena, Italy.

Massimo Maccherini (M)

Department of Cardiac Surgery, University of Siena, Siena, Italy.

Serafina Valente (S)

Division of Cardiology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.

Matteo Cameli (M)

Division of Cardiology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH